subject: Global Data: Neuropathic Pain - Pipeline Assessment and Market Forecasts [print this page] Global Data: Neuropathic Pain - Pipeline Assessment and Market Forecasts
GlobalData, the industry analysis specialist's new report, "Neuropathic Pain Drug Pipeline Analysis and Market Forecasts to 2015" is an essential source of information and analysis on the global neuropathic pain market. The report identifies the key trends shaping and driving the global neuropathic pain market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global neuropathic pain sector. GlobalData estimated the global neuropathic pain market to be valued at $4.8 billion in 2008. It is expected to grow at a Compound Annual Growth Rate (CAGR) of approximately 4.3% from $4.8 billion in 2008 to $6.5 billion in 2015. This growth will be supported by the increase in the aging population, increased treatment seeking behavior, increased uptake of the current products. Diagnosis rate remains as one of the barriers for the growth of the market. The available treatment options are moderately successful in meeting the market demand. There is still a need for better therapy and there exists the unmet need. There exists a market potential for any new entrant that will cater these unmet needs. There is enormous opportunity for any drug that would offer better or retain the efficacy provided by the current players with increased safety than the current products. GlobalData analyzed that there are over 139 molecules in various stages of the pipeline. Vimpat, Fentora are some of the pipeline candidates in the regulatory filing stage for approval. The late stage pipeline includes some of the promising molecules like Ralfinamide, NP-1, Sativex. These drugs may retain the similar efficacy and offer better safety and may benefit the patient population who cannot endure the available drugs. The newer therapies may intensify the existing competition and there seems to be a possibility of price war.
* Annualized global neuropathic pain market revenues data from 2006 to 2008, forecast forward for 7 years to 2015.
* Pipeline analysis data providing a split across different phases, mechanism of action being developed and emerging trends. Key classes of mechanism of action includes opioid receptor agonists, cannabinoid receptor modulators, NMDA antagonists, protein kinase inhibitors, ion channel targetters, serotonin norepinephrine reuptake inhibitors, adenosine agonists, cytokine modulators, AMPA antagonists, nicotinic receptor agonists, TRPV1 receptor agonists, selective subtype sodium channel antagonists, iNOS/nNOS dual inhibitors.
* Analysis of the current and future market competition in the global neuropathic pain market. Key future market players covered are NeurogesX, Cephalon Inc., UCB S.A., Newron Pharmaceuticals, EpiCept Corporation, GW Pharmaceuticals, Johnson & Johnson, Avanir pharmaceuticals, GlaxoSmithKline plc, AstraZeneca.
* Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
* Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for future market associated with neuropathic pain.
GlobalData is a UK-based company with presence across North America, Europe and Asia Pacific and has a broad product offering that ranges from interactive databases, reports and custom solutions. It is a comprehensive source of insights and analysis with coverage including oil & gas, power, alternative energy, nuclear power, petrochemicals, medical equipment and healthcare industries.
Visit our Report Store
http://www.globaldata.com/reportstore/
welcome to Insurances.net (https://www.insurances.net)
